Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience

Ulivi, Paola; Petracci, Elisabetta; Canale, Matteo; Priano, Ilaria; Capelli, Laura; Calistri, Daniele; Chiadini, Elisa; Cravero, Paola; Rossi, Alice; Delmonte, Angelo; Crinò, Lucio; Bronte, Giuseppe

doi:10.3390/biomedicines9101299

Cited by 12 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer (LC) is the main cause of cancer-related death worldwide [ 1 ]. Non-Small Cell Lung Cancer (NSCLC), the most common LC histology, is a heterogeneous malignancy comprising molecular subtypes for which targeted agents are available in clinical practice [ 2 ]. Epidermal Growth Factor Receptor ( EGFR ) is the most common altered targetable gene in NSCLC, and its mutations (mainly exon 19 deletions and exon 21 L8585R mutations) represent the predictive biomarker for first-, second- and third-generation EGFR -Tyrosine Kinase Inhibitors (TKIs).…”

Section: Introductionmentioning

confidence: 99%

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

Canale

Andrikou

Priano

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Oncogene-addicted patients usually benefit from targeted therapy, but primary and acquired resistance mechanisms inevitably occur. Tumor protein 53 (TP53) gene is the most frequently mutated gene in cancer, including NSCLC. TP53 mutations are able to induce carcinogenesis, tumor development and resistance to therapy, influencing patient prognosis and responsiveness to therapy. TP53 mutants present in different forms, suggesting that different gene alterations confer specific acquired protein functions. In recent years, many associations between different TP53 mutations and responses to Epidermal Growth Factor Receptor (EGFR) targeted therapy in NSCLC patients have been found. In this review, we discuss the current landscape concerning the role of TP53 mutants to guide primary and acquired resistance to Tyrosine-Kinase Inhibitors (TKIs) EGFR-directed, investigating the possible mechanisms of TP53 mutants within the cellular compartments. We also discuss the role of the TP53 mutations in predicting the response to targeted therapy with EGFR-TKIs, as a possible biomarker to guide patient stratification for treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

Canale

Andrikou

Priano

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although the development of gene detection technology is changing with each passing day, most of the rare mutations in the clinic cannot be identified. At present, some studies have found that 49 liquid biopsy analysis can be used as an alternative method for EGFR detection in tumor tissues, for patients with positive or negative EGFR in tumor biopsies, but most of the fluid biopsy analysis in this study was carried out in patients with advanced NSCLC during TKI treatment, and its clinical application needs to be further improved. One urgent task is to develop and use gene detection methods that can more accurately identify different rare EGFR mutations as soon as possible.…”

Section: Discussionmentioning

confidence: 99%

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer

Zhao

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) mutations are common driver genes in nonsmall-cell lung cancer and have different sensitivities to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). EGFR is divided into classic mutations and rare mutations. Classic mutations are well known, but the understanding of rare mutations is not sufficient. In this article, we summarize the clinical research and treatment progress of rare mutations for different EGFR-TKIs and provide a basis for clinical treatment decisions.

show abstract

“…Additionally, liquid biopsies enable the tracking of minimally recurrent illness, treatment efficacy, and the detection of clonal evolution or the establishment of resistance mutations. Additionally, studying ctDNA and CTCs in cases of haematological malignancies offers hope for disease monitoring and relapse prediction [ 76 , 77 ].…”

Section: Reviewmentioning

confidence: 99%

The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy

Shegekar,

Vodithala,

Juganavar

2023

Cureus

View full text Add to dashboard Cite

A potential non-invasive technique for identifying and tracking cancer is a liquid biopsy. This review article provides a comprehensive overview of the principles, applications, and challenges associated with liquid biopsies. The circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), exosomes, and microRNAs are just a few of the biomarkers we cover in this article that are discovered in liquid biopsies. The clinical application of liquid biopsies in many stages of cancer management, including early cancer identification, therapy selection and response monitoring, and minimum residual illness, is also investigated. The technical advancements in liquid biopsy techniques, including digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS), have improved the sensitivity and specificity of biomarker identification. Liquid biopsies require assistance with cost-effectiveness, sensitivity, and standardisation despite the potential benefits. We talk about these restrictions and potential solutions. In conclusion, liquid biopsies revolutionise personalised therapies and cancer diagnostics by providing a real-time, non-invasive tool for characterising and monitoring tumours. It will be possible to expand the use of liquid biopsies in clinical practises by having a better understanding of their current state and predicted future developments.

show abstract

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience

Cited by 12 publications

References 20 publications

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer

The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About